+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study



Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study



Diabetes 55(5): 1430-1435



This study was conducted to observe changes in insulin secretion and insulin action in subjects with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). A total of 319 subjects were studied with an oral glucose tolerance test (OGTT). Fasting plasma glucose and insulin concentrations were measured at baseline and every 30 min during the OGTT. Fifty-eight subjects also received a euglycemic-hyperinsulinemic clamp.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012220975

Download citation: RISBibTeXText

PMID: 16644701

DOI: 10.2337/db05-1200


Related references

Secretion and action of insulin among Han and Uygur subjects with impaired fasting glucose and impaired glucose tolerance from Xinjiang. Zhonghua Liu Xing Bing Xue Za Zhi 33(9): 961-963, 2012

Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects. Hypertension Research 31(7): 1357-1363, 2008

Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 26(3): 868-874, 2003

Insulin secretion and action show differences in impaired fasting glucose and in impaired glucose tolerance in Asian Indians. Diabetes/Metabolism Research and Reviews 19(4): 329-332, 2003

Insulin secretion and insulin resistance in impaired fasting glucose and impaired glucose tolerance subjects. Diabetologia 44(Suppl. 1): A 56, 2001

Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 32(3): 439-444, 2009

Different levels of thyroid hormones between impaired fasting glucose and impaired glucose tolerance: free T3 affects the prevalence of impaired fasting glucose and impaired glucose tolerance in opposite ways. Clinical Endocrinology 80(6): 890-898, 2014

Evaluation of antioxidative activity, insulin sensitivity and insulin secretion in early glucoregulation disorders-impaired fasting glucose and impaired glucose tolerance. Diabetes & Metabolism 29(Hors serie 2): 4S65, 2003

Serum high-molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus. Metabolism: Clinical and Experimental 58(10): 1470-1476, 2009

Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetologica 45(3): 147-150, 2008

Association of Albuminuria With Intraglomerular Hydrostatic Pressure and Insulin Resistance in Subjects With Impaired Fasting Glucose and/or Impaired Glucose Tolerance. Diabetes Care 41(11): 2414-2420, 2018

Differences in insulin resistance in non-diabetic subjects with impaired glucose tolerance and impaired fasting glucose. Diabetes 52(Suppl. 1): A220, 2003

The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. Diabetes Care 26(5): 1333-1337, 2003

A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes. Experimental and Clinical Endocrinology and Diabetes 116(5): 282-288, 2008

Evaluation of the safety, efficacy and tolerability of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset Type 2 diabetes. Diabetes & Metabolism 29(Hors serie 2): 4S230, 2003